$heff's $tation of $tocks & $olid DD

[Bob Stocks]

BIOD Phase 2 clinical trial for BIOD-123 done on July 11th...give 6 to 8 weeks to analyze data. Therefore, data to be release between August 22 to September 5th.
This stock is gonna double on Data imo. They are no strangers to insulin.

Date : 07/11/2013 @ 6:00AM


Biodel Announces Completion of Dosing in Phase 2 Clinical Trial of BIOD-123 in Patients With Type 1 Diabetes

Biodel Inc. (Nasdaq:BIOD) today announced that all scheduled follow-up visits have been completed for patients enrolled in the Phase 2 clinical trial of BIOD-123, an investigational ultra-rapid-acting injectable mealtime insulin therapy.

Dr. Errol De Souza, president and chief executive officer of Biodel, stated: "Completing the BIOD-123 Phase 2 clinical trial is another significant milestone in the development of novel ultra-rapid-acting mealtime insulins to aid patients and healthcare professionals in the treatment of diabetes. We look forward to sharing the top-line results by the end of this quarter."

Study Design

The Phase 2 clinical trial of BIOD-123 is a randomized, open label, parallel group study conducted at 33 investigative centers in the United States. In the trial, 132 patients with type 1 diabetes were randomized to receive either BIOD-123 or Humalog® to use as their mealtime insulin during an 18 week treatment period. Both arms of the study used insulin glargine, sold as Lantus®, as the basal insulin. The clinical trial is designed to evaluate HbA1c control as the primary endpoint, and secondary endpoints include postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.





http://ih.advfn.com/p.php?pid=nmona&article=58374706